Here's the short version. Zepbound, the weight-management brand of tirzepatide, has no established anxiety-treatment benefit. FDA's 2026 review and a large real-world comparison did not identify a clear overall increase in psychiatric risk [2] [3]. If your mood shifts on it, that's still worth a call to your prescriber.
Is Zepbound an anxiety treatment?
No. Its labeled uses are reducing excess weight and keeping it off, and treating moderate to severe obstructive sleep apnea in adults with obesity [1]. The cited evidence does not establish efficacy as an anxiety treatment.
That matters because "helps with anxiety" claims usually come from personal stories. Those are real experiences, but they can't separate the drug from everything else that changes during weight loss.
Does Zepbound cause anxiety?
Anxiety isn't listed among Zepbound's side effects, and large analyses haven't found a clear increase [1] [3]. The label's patient guide does list anxiety, irritability and mood changes, but as signs of low blood sugar.
One large comparison drew from a health-record network containing more than 192 million patients [3]. It matched about 85,500 adults starting tirzepatide with the same number starting semaglutide, then followed them for two years.
- Year one: similar risk of the combined psychiatric outcome (depression, anxiety or suicidal thoughts), hazard ratio 0.984 [3].
- Year two: still similar overall, hazard ratio 1.002 [3].
- The one signal: anxiety alone ran about 5% higher on tirzepatide in year two (hazard ratio 1.052). The authors said to interpret it cautiously, since they ran many comparisons [3].
Spontaneous reports tell a softer story. In a European database of 31,444 reports on three GLP-1 drugs, about 1.2% involved psychiatric events, with anxiety the second most common [4]. Reports like these can flag a question, but they can't show the drug caused anything.
What FDA concluded about mood and suicidal thoughts
On January 13, 2026, FDA asked the makers of GLP-1 weight-loss drugs to remove the suicidal behavior and ideation warning after its review found no increased risk [2]. The request covered Saxenda, Wegovy and Zepbound.
FDA's review pooled 91 placebo-controlled trials with 107,910 patients [2]. It found no higher rate of suicidal thoughts or behavior, or of other psychiatric effects such as anxiety, depression, irritability or psychosis. That's a large pool, though most of those trials weren't built to study mood. FDA also ran the records study below. That records analysis compared intentional self-harm with people starting a different diabetes drug class, SGLT2 inhibitors, and found no increased risk.
| Source | Type | Finding |
|---|---|---|
| Zepbound label (revised August 2026) [1] | FDA label | Suicidal behavior warning removed February 2026; anxiety not among listed side effects |
| FDA safety communication, January 13, 2026 [2] | Regulator review | 91 trials, 107,910 patients: no increased suicidal thoughts or other psychiatric effects; records study: no increased self-harm |
| Chen 2026 [3] | Records study, about 85,500 matched pairs | Tirzepatide similar to semaglutide for depression, anxiety and suicidal thoughts; year-two anxiety hazard ratio 1.052, nominal |
| Tobaiqy 2024 [4] | Spontaneous reports | Psychiatric events in 1.2% of reports; can't show cause |
Why some people feel better, or worse
People often report mood changes with weight loss, appetite change and side effects. These are experiences, not trial findings.
Tirzepatide acts on receptors found in brain areas that regulate appetite [1]. Whether that touches mood is a hypothesis, not something trials have shown. Nausea, poor sleep or eating much less can also leave you on edge.
Low blood sugar is a concrete cause to rule out. In a trial of people with type 2 diabetes, it happened in 4.2% on Zepbound vs 1.3% on placebo, and the risk is higher alongside insulin or a sulfonylurea [1]. Shakiness, a fast heartbeat and anxiety are among its listed signs. If tiredness is the bigger issue, see whether Zepbound affects energy.
When to call your prescriber
If anxiety, low mood or thoughts of self-harm are new or getting worse, contact your prescriber. FDA's own advice to patients is the same: report new or worsening depression or changes in mood [2].
A few notes make that visit more useful. Bring them written down.
- When the anxiety started, and whether it lines up with a dose change, skipped meals or poor sleep.
- Whether it comes with shakiness, sweating or a racing heart, which can point to low blood sugar.
- Any other new medicines, supplements, caffeine or alcohol changes since you started.
- Whether you've had anxiety or depression before, and what helped then.
Don't stop or change the dose on your own. Your prescriber can check for low blood sugar, side effects and other causes, and decide what to change.
Zepbound vs Wegovy on mood
Semaglutide's pooled STEP trials found no increase in depressive symptoms or suicidal thoughts vs placebo [5]. Depression scores even dipped slightly, though not by a clinically meaningful amount.
In the 2026 records study, semaglutide also had lower psychiatric event rates than older GLP-1 drugs in year one [3]. For more on semaglutide and the brain, see what Ozempic does to your brain.
If your goal is weight and metabolic health, start with the metabolic shortlist. If you're training while on tirzepatide, see can you build muscle on tirzepatide.